Breaking News Instant updates and real-time market news.

UNH

UnitedHealth

$222.77

-2.66 (-1.18%)

, GSK

GlaxoSmithKline

$37.65

0.29 (0.78%)

08:00
03/13/18
03/13
08:00
03/13/18
08:00

UnitedHealth: Renfro to lead enterprisewide growth efforts, Optum Ventures funds

UnitedHealth Group (UNH) announced Larry C. Renfro, vice chair of UnitedHealth Group and CEO of Optum, will lead UnitedHealth Group's enterprise growth efforts and Optum's next-generation investment initiatives through an expanded Optum Ventures. Andrew Witty will join UnitedHealth Group, succeeding Renfro as CEO of Optum, effective July 1, 2018. Witty is the former CEO of GlaxoSmithKline plc (GSK) and has served as a member of the UnitedHealth Group board of directors since August 2017. Renfro will focus his work on UnitedHealth Group growth priorities and developing, maintaining and expanding strategic relationships, sponsorships and partnerships worldwide. Renfro will help accelerate the company's innovation capacities and reach as managing partner of Optum Ventures, a series of domestic and international funds, including a new, $100 million Global Fund, dedicated to emerging and advanced technology, data analytics and health care services companies with transformative capabilities to make health care better for everyone. The new global fund complements the domestic Optum Ventures fund announced in November 2017; together they have total investment commitments of up to $600M. In light of his new appointment, Witty will step down from the UnitedHealth Group board of directors, effective immediately.

UNH

UnitedHealth

$222.77

-2.66 (-1.18%)

GSK

GlaxoSmithKline

$37.65

0.29 (0.78%)

  • 13

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    May

UNH UnitedHealth
$222.77

-2.66 (-1.18%)

03/13/18
ADAM
03/13/18
NO CHANGE
Target $90
ADAM
Buy
Insulet improved market access reinforces growth opportunity, says Canaccord
Canaccord analyst Kyle Rose noted UnitedHealth (UNH) has agreed to cover the Insulet (PODD) OmniPod for its 70M covered lives. The announcement provides a meaningful growth opportunity for 2018 and beyond. The increased market access reinforces his conviction that Insulet remains in the early stages of a transformative period of meaningful market share gains. Rose reiterated his Buy rating and raised his price target to $90 from $88 on Insulet shares.
03/12/18
WBLR
03/12/18
NO CHANGE
WBLR
Outperform
Insulet announced coverage win with UnitedHealth, says William Blair
Insulet (PODD) on Friday announced it had established a new contract with UnitedHealthcare (UNH), which would provide its patients with in-network, durable medical equipment coverage for Omnipod beginning April 1, William Blair analyst Margaret Kaczor tells investors in a research note. This is another coverage win for Insulet as UnitedHealth represents almost 50M lives in the United States, the analyst adds. She notes Insulet has had limited access to historically a Medtronic (MDT) has been UnitedHealth's preferred, in-network DME insulin pump provider since mid-2016. Kaczor views the announcement as "another improvement in patient access to Omnipod." She thinks Insulet "continues to fire on all cylinders" and keeps an Outperform rating on the shares.
03/10/18
PIPR
03/10/18
NO CHANGE
Target $88
PIPR
Overweight
Insulet scores 'nice win' at UnitedHealth into weekend, says Piper Jaffray
Insulet (PODD) and UnitedHealth (UNH) announced yesterday afternoon an in-network contract for Omnipod which goes into effect April 1, Piper Jaffray analyst JP McKim tells investors in a research note. Omnipod is Insulet's tubeless insulin pump to monitor type 1 diabetes. The agreement affects commercial and Medicaid lives, the analyst points out. He views the news as a "nice win" for Insulet and expects the shares to react favorably. McKim continues to recommend Insulet with an Overweight rating and sees the stock pushing towards his $88 price target. The shares closed Friday up 67c to $80.33.
03/08/18
PIPR
03/08/18
NO CHANGE
Target $226
PIPR
Overweight
Cigna deal for Express Scripts makes Medicaid or MA deal less likely, says Piper Jaffray
Piper Jaffray analyst Sarah James said she does not see any issues with Cigna (CI) obtaining approval of its deal to buy Express Scripts (ESRX), even though the deal will give the combined company annual script volume of 848M, making it the third-largest PBM. She does not think Cigna's script volume would transition to the combined entity until 2023, which is when Cigna's contract with UnitedHealth's (UNH) OptumRx ends. Also, James thinks this deal makes it less likely in the near-term that Cigna would buy a Medicaid or Medicare Advantage plan. The analyst has an Overweight rating and $226 price target on Cigna shares.
GSK GlaxoSmithKline
$37.65

0.29 (0.78%)

02/22/18
LEER
02/22/18
NO CHANGE
LEER
Rapid adoption of Gilead Biktarvy to challenge GlaxoSmithKline outlook, says Leerink
Leerink analyst Seamus Fernandez notes he has recently completed a MEDACorp survey of U.S. HIV treatment specialists and has found "impressively positive" sentiment about Gilead's (GILD) Biktarvy which seems likely to put sustained pressure on GlaxoSmithKline's (GSK) leading integrase inhibitor Tivicay, as well as cannibalizing Gilead's other combination and component products.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.

TODAY'S FREE FLY STORIES

RARX

RA Pharmaceuticals

$16.45

0.25 (1.54%)

07:07
12/10/18
12/10
07:07
12/10/18
07:07
Hot Stocks
RA Pharmaceuticals says Phase 2 trial of zilucoplan meets primary endpoint »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PBA

Pembina Pipeline

$32.52

-0.47 (-1.42%)

07:07
12/10/18
12/10
07:07
12/10/18
07:07
Hot Stocks
Pembina Pipeline announces 2019 capital program of $1.6B »

Pembina Pipeline is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPTN

Optinose

$8.08

0.2 (2.54%)

07:06
12/10/18
12/10
07:06
12/10/18
07:06
Hot Stocks
Optinose announces first patient enrolled in XHANCE clinical trial »

Optinose announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BLNK

Blink Charging

$2.11

(0.00%)

07:05
12/10/18
12/10
07:05
12/10/18
07:05
Initiation
Blink Charging initiated  »

Blink Charging initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNLO

Menlo Therapeutics

$5.69

0.13 (2.34%)

07:05
12/10/18
12/10
07:05
12/10/18
07:05
Hot Stocks
Menlo Therapeutics says serlopitant successfully met primary endpoint in trial »

Menlo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHC

A.H. Belo

$4.33

-0.1 (-2.26%)

07:05
12/10/18
12/10
07:05
12/10/18
07:05
Hot Stocks
A.H. Belo announces termination of agreement to sell $33M Dallas property »

A. H. Belo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda Pharmaceuticals

$27.56

-1.85 (-6.29%)

07:05
12/10/18
12/10
07:05
12/10/18
07:05
Hot Stocks
Vanda Pharmaceuticals announces 'positive' study results for HETLIOZ »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXSM

Axsome Therapeutics

$2.97

-0.17 (-5.41%)

07:04
12/10/18
12/10
07:04
12/10/18
07:04
Hot Stocks
Axsome: IDMC recommends continuation of trial evaluating AXS-05 in AD »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTEK

Fuel Tech

$1.30

-0.02 (-1.52%)

07:03
12/10/18
12/10
07:03
12/10/18
07:03
Initiation
Fuel Tech initiated  »

Fuel Tech initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$28.73

-1.32 (-4.39%)

07:02
12/10/18
12/10
07:02
12/10/18
07:02
Downgrade
Navistar rating change  »

Navistar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

ACB

Aurora Cannabis

$5.73

0.46 (8.73%)

07:02
12/10/18
12/10
07:02
12/10/18
07:02
Hot Stocks
Aurora Cannabis to acquire Farmacias Magistrales S.A. »

Aurora Cannabis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,036.52

-33.18 (-3.10%)

, GOOGL

Alphabet Class A

$1,046.99

-31.41 (-2.91%)

06:59
12/10/18
12/10
06:59
12/10/18
06:59
Periodicals
Google focuses on preventing leaks to the media, The Times reports »

Jack Poulson, a former…

GOOG

Alphabet

$1,036.52

-33.18 (-3.10%)

GOOGL

Alphabet Class A

$1,046.99

-31.41 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

OSK

Oshkosh

$66.69

-1.38 (-2.03%)

06:57
12/10/18
12/10
06:57
12/10/18
06:57
Downgrade
Oshkosh rating change  »

Oshkosh downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$201.25

-13.09 (-6.11%)

06:54
12/10/18
12/10
06:54
12/10/18
06:54
Downgrade
FedEx rating change  »

FedEx downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BABA

Alibaba

$153.09

-2.7 (-1.73%)

06:54
12/10/18
12/10
06:54
12/10/18
06:54
Periodicals
Alibaba to control Alibaba Pictures with $159.9M share purchase, Reuters says »

Alibaba will increase its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTAI

Fortress Transportation

$15.23

-0.13 (-0.85%)

06:52
12/10/18
12/10
06:52
12/10/18
06:52
Hot Stocks
Fortress Transportation terminal awarded $20M Federal grant »

Congress recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAPO

Vapotherm

$20.75

0.5 (2.47%)

06:52
12/10/18
12/10
06:52
12/10/18
06:52
Initiation
Vapotherm initiated  »

Vapotherm initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$5.29

-0.17 (-3.11%)

06:51
12/10/18
12/10
06:51
12/10/18
06:51
Initiation
Internap initiated  »

Internap initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$112.00

-1.385 (-1.22%)

, FOX

21st Century Fox

$48.99

-0.23 (-0.47%)

06:51
12/10/18
12/10
06:51
12/10/18
06:51
Periodicals
Disney, Comcast to spend a combined $43B on content in 2018, WSJ reports »

Walt Disney's (DIS)…

DIS

Disney

$112.00

-1.385 (-1.22%)

FOX

21st Century Fox

$48.99

-0.23 (-0.47%)

FOXA

21st Century Fox

$49.26

-0.21 (-0.42%)

CMCSA

Comcast

$37.41

-0.46 (-1.21%)

CMCSK

Comcast

$0.00

(0.00%)

SKYAY

Sky

$0.00

(0.00%)

NFLX

Netflix

$265.14

-17.66 (-6.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDIUY

Mediaset

$0.00

(0.00%)

06:51
12/10/18
12/10
06:51
12/10/18
06:51
Downgrade
Mediaset rating change  »

Mediaset downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RY

Royal Bank of Canada

$71.07

-0.55 (-0.77%)

06:49
12/10/18
12/10
06:49
12/10/18
06:49
Upgrade
Royal Bank of Canada rating change  »

Royal Bank of Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

AUY

Yamana Gold

$2.26

0.075 (3.43%)

06:49
12/10/18
12/10
06:49
12/10/18
06:49
Downgrade
Yamana Gold rating change  »

Yamana Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DK

Delek US

$37.83

-0.72 (-1.87%)

06:48
12/10/18
12/10
06:48
12/10/18
06:48
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YELP

Yelp

$34.60

0.19 (0.55%)

06:47
12/10/18
12/10
06:47
12/10/18
06:47
Hot Stocks
Yelp says 'we maintain an ongoing dialogue with all of our shareholders' »

Yelp issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

URI

United Rentals

$103.93

-0.81 (-0.77%)

06:46
12/10/18
12/10
06:46
12/10/18
06:46
Conference/Events
United Rentals to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 13

    Dec

  • 14

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.